½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1322268

¼¼°èÀÇ ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ(ALS, ·ç°Ô¸¯º´) Ä¡·á ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2031³â)

Amyotrophic Lateral Sclerosis Treatment Market (Type: Sporadic ALS and Familial ALS; Treatment: Medication, Stem Cell Therapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀå-º¸°í¼­ ¹üÀ§

¼¼°èÀÇ ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ(ALS, ·ç°Ô¸¯º´) Ä¡·á(Amyotrophic Lateral Sclerosis Treatment) ½ÃÀå¿¡ ´ëÇÑ TMR º¸°í¼­´Â °ú°Å ¹× ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú 2023³â¿¡¼­ 2031³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥ÀÇ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ¾òÀ» ±âȸ¸¦ ¿¬±¸ÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â 2023³âÀ» ±âÁس⵵, 2031³âÀ» ¿¹Ãø³âµµ·Î ÇÏ¿©, 2017³âºÎÅÍ 2031³â±îÁöÀÇ ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀåÀÇ ¼öÀÍÀ» °ÔÀçÇÕ´Ï´Ù. ¶ÇÇÑ 2023³âºÎÅÍ 2031³â±îÁö ¼¼°èÀÇ ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀåÀÇ CAGR(%)µµ Á¦°øÇÕ´Ï´Ù.

º¸°í¼­´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ °ÅÃÄ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼­´Â Á¶»ç È°µ¿ÀÇ ´ëºÎºÐÀÌ ÀÌ·ç¾îÁ³À¸¸ç ºÐ¼®°¡µéÀº ÁÖ¿ä ¿ÀÇǴϾ𠸮´õ, »ê¾÷ ¸®´õ, ¿ÀÇǴϾð Á¦Á¶»ç¿Í ÀÎÅͺ並 ½Ç½ÃÇß½À´Ï´Ù. 2Â÷ Á¶»ç¿¡´Â ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀåÀ» ÀÌÇØÇϱâ À§ÇØ ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ¹®Çå, ¿¬·Ê º¸°í¼­, º¸µµ ÀÚ·á ¹× °ü·Ã ¹®¼­¿¡ ´ëÇÑ ÂüÁ¶°¡ Æ÷ÇԵ˴ϴÙ.

¼¼°èÀÇ ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀå °æÀï »óȲÀ» ÆľÇÇÏ°í ÀÖ½À´Ï´Ù. ¼¼°è ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀå¿¡¼­ È°µ¿ÇÏ´Â ÁÖ¿ä Ç÷¹À̾ È®ÀεǾúÀ¸¸ç, ÀÌµé °¢°¢Àº ´Ù¾çÇÑ ¼Ó¼º °üÁ¡¿¡¼­ ÇÁ·ÎÆÄÀϸµµË´Ï´Ù. ȸ»ç °³¿ä, À繫 »óȲ, ÃÖ±Ù µ¿Çâ, SWOT´Â ÀÌ º¸°í¼­¿¡ ¼Ò°³ µÈ ¼¼°èÀÇ ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀå Ç÷¹À̾îÀÇ ¼Ó¼ºÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÀüÁ¦ Á¶°Ç ¹× ¿¬±¸ Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼Ò°³
  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • Àü ¼¼°è ½ÃÀå ºÐ¼® ¹× ¿¹Ãø(2017-2031³â)

Á¦5Àå ÁÖ¿ä ÅëÂû

  • Áö¿ªº°/¼¼°è ÀüüÀÇ ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • COVID-19ÀÇ ÆÒµ¥¹ÍÀÌ »ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦6Àå ½ÃÀå ºÐ¼® ¹× ¿¹Ãø : À¯Çüº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä °á°ú ¹× °³¹ß
  • ½ÃÀå ±Ý¾× ¿¹Ãø : À¯Çüº°(2017-2031³â)
    • »ê¹ß¼º ALS
    • °¡Á·¼º ALS
  • ½ÃÀå ¸Å·Â ºÐ¼® : À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® ¹× ¿¹Ãø : Ä¡·á¹ýº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä °á°ú ¹× °³¹ß
  • ½ÃÀå ±Ý¾× ¿¹Ãø : Ä¡·áº°(2017-2031³â)
    • Åõ¾à
    • Áٱ⼼Æ÷Ä¡·á
    • ±âŸ
  • ½ÃÀå ¸Å·Â ºÐ¼® : Ä¡·á¹ýº°

Á¦8Àå ½ÃÀå ºÐ¼® ¹× ¿¹Ãø : À¯Åë ä³Îº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä °á°ú ¹× °³¹ß
  • ½ÃÀå ±Ý¾× ¿¹Ãø : À¯Åë ä³Îº°(2017-2031³â)
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ±âŸ
  • ½ÃÀå ¸Å·Â ºÐ¼® : À¯Åë ä³Îº°

Á¦9Àå ½ÃÀå ºÐ¼® ¹× ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ±Ý¾× ¿¹Ãø : Áö¿ªº°
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç Áö¿ª
    • ³²¹Ì
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°

Á¦10Àå ºÏ¹Ì ½ÃÀå ºÐ¼® ¹× ¿¹Ãø

Á¦11Àå À¯·´ ½ÃÀå ºÐ¼® ¹× ¿¹Ãø

Á¦12Àå ¾Æ½Ã¾Æ ÅÂÆò¾ç ½ÃÀå ºÐ¼® ¹× ¿¹Ãø

Á¦13Àå ³²¹Ì ½ÃÀå ºÐ¼® ¹× ¿¹Ãø

Á¦14Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼® ¹× ¿¹Ãø

Á¦15Àå °æÀï »óȲ

  • ½ÃÀå ÁøÀÔ ±â¾÷-°æÀï ¸ÅÆ®¸¯½º(±â¾÷ÀÇ °èÃþ ¹× ±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ±â¾÷º°(2022³â)
  • ±â¾÷ °³¿ä
    • Mitsubishi Tanabe Pharma Corporation
    • Otsuka Pharmaceutical Co., Ltd.
    • BrainStorm Therapeutics
    • Biogen, Inc.
    • Corestem
    • AB Science
    • F. Hoffmann-La Roche AG
    • Biohaven Pharmaceutical
    • Sun Pharmaceutical
    • Other Prominent Players
LYJ 23.10.10

Amyotrophic Lateral Sclerosis Treatment Market - Scope of Report

TMR's report on the global Amyotrophic Lateral Sclerosis Treatment Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Amyotrophic Lateral Sclerosis Treatment Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Amyotrophic Lateral Sclerosis Treatment Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Amyotrophic Lateral Sclerosis Treatment Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Amyotrophic Lateral Sclerosis Treatment Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Amyotrophic Lateral Sclerosis Treatment Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Amyotrophic Lateral Sclerosis Treatment Market.

The report delves into the competitive landscape of the global Amyotrophic Lateral Sclerosis Treatment Market. Key players operating in the global Amyotrophic Lateral Sclerosis Treatment Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Amyotrophic Lateral Sclerosis Treatment Market profiled in this report.

Key Questions Answered in Global Amyotrophic Lateral Sclerosis Treatment Market Report:

  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Amyotrophic Lateral Sclerosis Treatment Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Amyotrophic Lateral Sclerosis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global Amyotrophic Lateral Sclerosis Treatment Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Amyotrophic Lateral Sclerosis Treatment Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Amyotrophic Lateral Sclerosis Treatment.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Amyotrophic Lateral Sclerosis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario by Region/globally
  • 5.2. Pipeline Analysis
  • 5.3. Pricing Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Sporadic ALS
    • 6.3.2. Familial ALS
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Treatment

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Treatment, 2017-2031
    • 7.3.1. Medication
    • 7.3.2. Stem Cell Therapy
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Treatment

8. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Type, 2017-2031
    • 10.2.1. Sporadic ALS
    • 10.2.2. Familial ALS
  • 10.3. Market Value Forecast, by Treatment, 2017-2031
    • 10.3.1. Medication
    • 10.3.2. Stem Cell Therapy
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Type
    • 10.6.2. By Treatment
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. Sporadic ALS
    • 11.2.2. Familial ALS
  • 11.3. Market Value Forecast, by Treatment, 2017-2031
    • 11.3.1. Medication
    • 11.3.2. Stem Cell Therapy
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Type
    • 11.6.2. By Treatment
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. Sporadic ALS
    • 12.2.2. Familial ALS
  • 12.3. Market Value Forecast, by Treatment, 2017-2031
    • 12.3.1. Medication
    • 12.3.2. Stem Cell Therapy
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Type
    • 12.6.2. By Treatment
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Sporadic ALS
    • 13.2.2. Familial ALS
  • 13.3. Market Value Forecast, by Treatment, 2017-2031
    • 13.3.1. Medication
    • 13.3.2. Stem Cell Therapy
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Type
    • 13.6.2. By Treatment
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. Sporadic ALS
    • 14.2.2. Familial ALS
  • 14.3. Market Value Forecast, by Treatment, 2017-2031
    • 14.3.1. Medication
    • 14.3.2. Stem Cell Therapy
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Type
    • 14.6.2. By Treatment
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2022
  • 15.3. Company Profiles
    • 15.3.1. Mitsubishi Tanabe Pharma Corporation
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Otsuka Pharmaceutical Co., Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. BrainStorm Therapeutics
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Biogen, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Corestem
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. AB Science
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F. Hoffmann-La Roche AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Biohaven Pharmaceutical
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Sun Pharmaceutical
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Other Prominent Players
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦